Skip to content

A randomized controlled study of pharmacists' intervention model for the management of antithrombotic drug compliance

A randomized controlled study of pharmacists' intervention model for the management of antithrombotic drug compliance

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085994
Enrollment
Unknown
Registered
2024-06-23
Start date
2024-07-01
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thrombosis, recurrent abortion, preeclampsia, etc

Interventions

Pharmacists intervention group:(1) Provide medication education for patients using antithrombotic drugs, including storage, usage, indications, adverse reactions, drug interactions, etc.
(2) Conduct targeted re-education on the results of filling in the cognitive assessment scale and compliance assessment scale, confirm the correct ones, explain the wrong ones and tell the correct ans
non-pharmacists intervention group:No intervention,only the basic information provided by the doctor during the patients visit.

Sponsors

Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years 2. Antithrombotic therapy(Aspirin, heparin, etc.) continues for at least 2 weeks 3. Follow up.

Exclusion criteria

Exclusion criteria: 1. The information about cognitive impairment was retrieved by the hospital electronic medical record system 2. Severe liver insufficiency (Total bilirubin was more than twice the upper limit of normal, and AST/ALT/ALP was more than three times the upper limit of normal) 3. Severe renal insufficiency 4. History of gastrointestinal hemorrhage, cerebral hemorrhage, or other severe bleeding in the last 3 months [bleeding resulting in hemoglobin reduction =20g/L(1.24mmol/L); or bleeding requiring infusion of =2 units of red blood cells].

Design outcomes

Primary

MeasureTime frame
Morisky-8 scale evaluation results;Percentage of patients with PDC (the proportion of days covered) = 80%;

Secondary

MeasureTime frame
Bleeding rate, thrombosis rate, gastrointestinal adverse reactions, re-hospitalization rate due to antithrombotic drugs, pregnancy outcomes, etc.;Disease and drug cognition;Satisfaction degree;

Countries

China

Contacts

Public ContactJinhua Zhang

Fujian Maternity and Child Health Hospital

pollyzhang2006@126.com+86 133 0691 2381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026